Loading organizations...
Loading organizations...
Genome editing technology for human health and gene therapy.
EdiGene has raised $164.4M across 5 funding rounds.
EdiGene has raised $164.4M in total across 5 funding rounds.
EdiGene has raised $164.4M in total across 5 funding rounds.
EdiGene's investors include Andy Lin, 3H Health Investment, Hongshan Capital Group (Sequoia Capital China), Huagai Capital, IDG Capital, Kunlun Capital, Lilly Asia Ventures, Sherpa Healthcare Partners, Minchuan Wang, Green Pine Capital Partners, Fei Luo, Fei Chen.
EdiGene has raised $164.4M across 5 funding rounds. Most recently, it raised $61.5M Series B in April 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 21, 2021 | $61.5M Series B | Andy Lin | 3H Health Investment, Hongshan Capital Group (Sequoia Capital China), Huagai Capital, IDG Capital, Kunlun Capital, Lilly Asia Ventures, Sherpa Healthcare Partners |
| Oct 13, 2020 | $66.9M Series B | Minchuan Wang | Green Pine Capital Partners, Hongshan Capital Group (Sequoia Capital China), Huagai Capital, IDG Capital, Kunlun Capital, Lilly Asia Ventures |
| Sep 16, 2019 | $11.0M Pre-Series B | IDG Capital, Lilly Asia Ventures | |
| Feb 4, 2019 | $10.0M Pre-Series B | Fei Luo | IDG Capital, Lilly Asia Ventures |
| Aug 8, 2018 | $15.0M Pre-Series B | Fei Chen | Huagai Capital, IDG Capital, WI Harper Group |